gefitinib has been researched along with hki 272 in 24 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (hki 272) | Trials (hki 272) | Recent Studies (post-2010) (hki 272) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 283 | 42 | 248 |
| Protein | Taxonomy | gefitinib (IC50) | hki 272 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0416 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0298 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.8582 | |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | 0.274 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A | 1 |
| Alberti, JG; Alligood, KJ; Caferro, TR; Chamberlain, SD; Dickerson, SH; Dickson, HD; Emerson, HK; Gerding, RM; Griffin, RJ; Hubbard, RD; Keith, BR; Mullin, RJ; Petrov, KG; Reno, MJ; Rheault, TR; Rusnak, DW; Sammond, DM; Smith, SC; Stevens, KL; Uehling, DE; Waterson, AG; Wood, ER | 1 |
| Bikker, JA; Brooijmans, N; Mansour, TS; Wissner, A | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Bantscheff, M; Bergamini, G; Gohlke, B; Gupta, V; Handa, H; Heinzlmeir, S; Helm, D; Klaeger, S; Kuster, B; Médard, G; Perrin, J; Preissner, R; Qiao, H; Savitski, MM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Basetti, V; Keesara, M; Maiti, P; Mansour, TS; Moghudula, AG; Pallepati, RR; Potluri, V | 1 |
| Bauer, S; Baumann, M; Becker, C; Grabe, T; Hardick, J; Hodson, L; Jeyakumar, K; Ketzer, J; Keul, M; Kirschner, T; Klövekorn, P; Lategahn, J; Müller, MP; Niggenaber, J; Rauh, D; Terheyden, S; Tumbrink, HL; Unger, A; van Otterlo, WAL; Weisner, J | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Riely, GJ | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Gong, Y; Pao, W | 1 |
| Antalffy, G; Hegedüs, C; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Settleman, J; Szakács, G; Truta-Feles, K; Váradi, A; Várady, G | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Eisenstein, M | 1 |
| Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
1 review(s) available for gefitinib and hki 272
| Article | Year |
|---|---|
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
23 other study(ies) available for gefitinib and hki 272
| Article | Year |
|---|---|
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ErbB Receptors; Mice; Pharmacokinetics; Pyrimidines; Pyrrolidines; Receptor, ErbB-2; Structure-Activity Relationship | 2009 |
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Topics: Amino Acid Sequence; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Molecular Sequence Data; Mutation; Neoplasms; Phosphotransferases; Protein Conformation | 2009 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
Topics: Exons; Humans; Mutation; Protein Kinase Inhibitors; Thioctic Acid | 2019 |
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
Topics: Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Kinetics; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
EGFR mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines | 2012 |
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Piperidines; Protein Binding; Quinazolines; Quinolines | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Clinical trials: More trials, fewer tribulations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size | 2014 |
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolines; Receptor, ErbB-2; Tamoxifen | 2015 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |